BLUE News Alert Bluebird Bio Inc (BLUE) 91.26 01/03/2015 13:

New Post Public Reply Private Reply Replies (0) Message Board

Jan 3, 2015 at 2:29 PM

Bluebird Bio Inc (BLUE) 91.26 $BLUE

How These 3 Stocks Doubled Investors' Money in Q4
Todd Campbell, The Motley Fool - Motley Fool - Sat Jan 03, 9:31AM CST
Source: Flickr user Tax Credits Most of the time, life-changing financial gains are generated over the long haul, not in the blink of an eye. However, sometimes stocks can put up jaw-dropping returns over a short period of time too. For example,...
BLUE: 91.26 (-0.46), ISIS: 61.57 (-0.17), ALNY: 97.77 (+0.77), OVAS: 45.83 (+1.61), GILD: 94.91 (+0.65), RGLS: 17.19 (+1.15), CELG: 113.52 (+1.66)

The Market's Top 10 Stocks of 2014
Dan Caplinger, The Motley Fool - Motley Fool - Sat Jan 03, 8:00AM CST
For six years now, investors have looked with skepticism at the rise in the stock market. And for a sixth straight year, the markets defied those who were waiting for a major downturn to invest, with the S&P 500 climbing about 14% including...
BLUE: 91.26 (-0.46), TTPH: 39.72 (+0.01), AVNR: 16.94 (-0.01), SWKS: 73.32 (+0.61), CMRX: 41.78 (+1.52), ACHN: 13.33 (+1.08), HA: 25.27 (-0.78), RCPT: 124.81 (+2.30), PTCT: 51.00 (-0.77), AGIO: 109.76 (-2.28)

Cellectis Is Late To The CAR-T Cell Race, But Could Finish First
Intrepid Investor - at Seeking Alpha - Fri Jan 02, 3:21PM CST

BLUE: 91.26 (-0.46), BLCM: 22.86 (-0.18), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97), GSK: 42.37 (-0.37), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66)

Biotech Stocks 2014: The Best, Worst and Fastest-Growing
at The Street - Fri Jan 02, 7:33AM CST
Once again, biotech stocks greatly outperformed the broader market in 2014.
BLUE: 91.26 (-0.46), OVAS: 45.83 (+1.61), ACHN: 13.33 (+1.08), RCPT: 124.81 (+2.30), AGIO: 109.76 (-2.28)

Biotech-Twitter 2014: A Look Back at the Biotech Year Through the Twitter Lens
at The Street - Mon Dec 29, 5:00AM CST
Another crazy and profitable year in biotech investing was captured 140 characters at a time.
BLUE: 91.26 (-0.46), NWBO: 5.42 (+0.07), GILD: 94.91 (+0.65), DNDN: 0.13 (-0.02), ICPT: 159.49 (+3.49), JUNO: 48.25 (-3.97), GALE: 1.56 (+0.05), AGIO: 109.76 (-2.28), AEGR: 21.58 (+0.64), ABBV: 65.89 (+0.45), BMY: 59.51 (+0.48), MNKD: 5.64 (+0.42), CELG: 113.52 (+1.66)

INVESTOR ALERT: The Law Firm of Levi & Korsinsky, LLP Launches an Investigation into bluebird bio, Inc. Regarding Possible Breaches of Fiduciary Duty
Business Wire - Tue Dec 23, 12:41PM CST
Levi & Korsinsky, LLP is investigating bluebird bio, Inc. (Nasdaq: BLUE) in connection with possible claims of breaches of fiduciary duty by the board of directors of the Company.
BLUE: 91.26 (-0.46)

3 Clinical Stage Biotech Stocks That Should Be on Your Watchlist in 2015
Motley Fool Staff - Motley Fool - Tue Dec 23, 6:07AM CST
Source: Celgene Corp Biotech stocks are notorious for their stratospheric gains and subterranean losses, especially clinical stage biotech stocks that develop promising, yet unproven, next-generation drugs. Those emerging biotech stocks may offer...
BLUE: 91.26 (-0.46), GSK: 42.37 (-0.37), BMY: 59.51 (+0.48), NVS: 92.25 (-0.41), CELG: 113.52 (+1.66), FPRX: 27.71 (+0.71), EXEL: 1.65 (+0.21)

Cramer's Mad Money - Look At Red Hat Go (12/19/14)
SA Editor Miriam Metzinger - at Seeking Alpha - Sun Dec 21, 4:26AM CST
Stocks discussed on the in-depth session of Jim Cramer's Mad Money TV Program, Friday December 19. CEO Interview, James Whitehurst, Red Hat (NYSE: RHT ) "Look at Red Hat ( RHT ) run." The stock dominates Open Source software for...
BLUE: 91.26 (-0.46), GPRO: 66.87 (+3.65), AVP: 9.31 (-0.08), SYNA: 64.25 (-4.59), NKE: 95.03 (-1.12), SKX: 55.74 (+0.49), DECK: 89.74 (-1.30), DIS: 93.75 (-0.44), CSIQ: 24.69 (+0.50), PAYX: 46.24 (+0.07), RDNT: 8.66 (+0.12), KITE: 60.61 (+2.94), RHT: 68.99 (-0.15), HAWK: 37.01 (-1.79), JUNO: 48.25 (-3.97), PAY: 37.35 (+0.15), WAG: 76.05 (-0.49)

The Winners for Best and Worst Biotech CEOs of 2014 Are...
at The Street - Thu Dec 18, 9:01AM CST
Congrats to David Schenkhein of Agios and Nick Leschly of Bluebird Bio for snagging 'Best' honors, while the ignominious (dis)honor of 'Worst' goes to Martin Shkreli, formerly of Retrophin.
BLUE: 91.26 (-0.46), RTRX: 12.67 (+0.43), AGIO: 109.76 (-2.28)

2014 Healthcare Stock Report Card: Sobek Tracks His Hits and Misses
at The Street - Thu Dec 18, 8:35AM CST
Gilead, Sangamo and Bluebird were great calls, Alexion and Vertex not so much.
BLUE: 91.26 (-0.46), VRTX: 123.07 (+4.27), GILD: 94.91 (+0.65), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), SGMO: 15.27 (+0.06)

Juno Therapeutics: Saving The Best Biotech IPO For Last In 2014
Chris Katje - at Seeking Alpha - Wed Dec 17, 10:13AM CST

BLUE: 91.26 (-0.46), KITE: 60.61 (+2.94), JUNO: 48.25 (-3.97)

2015 Biotech Drug/Stock Outlook: Here's What You Need to Know
at The Street - Wed Dec 17, 8:20AM CST
To prep investors for 2015, a list of clinical trial read-outs and FDA events expected to have a significant impact on stock prices in the first half of next year.
BLUE: 91.26 (-0.46), BIIB: 342.01 (+2.56), VRTX: 123.07 (+4.27), NBIX: 22.84 (+0.50), GILD: 94.91 (+0.65), ARWR: 7.71 (+0.33), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), CTIC: 2.40 (+0.04), CEMP: 22.89 (-0.62), BMY: 59.51 (+0.48)

'Mad Money' Lightning Round: Enbridge Energy Partners Is a Great Stock
at The Street - Wed Dec 17, 5:00AM CST
Cramer says to wait on buying Chevron and Bluebird Bio until their shares are lower and stay away from EV Energy Partners.
BLUE: 91.26 (-0.46), TTWO: 28.09 (+0.06), ATVI: 20.13 (-0.02), SAIC: 49.50 (-0.03), EVEP: 21.01 (+1.74), ONVO: 7.29 (+0.04), TRN: 28.28 (+0.27), CVX: 112.58 (+0.40), EEP: 40.55 (+0.65)

Cramer's Lightning Round - Chevron Is Worth The Wait (12/16/14)
SA Editor Miriam Metzinger - Seeking Alpha - Wed Dec 17, 4:03AM CST
Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday December 16. Bullish Calls: Chevron (NYSE: CVX ): "CVX has a nice yield and it is good. You are going to have to wait till around $95 with a...
BLUE: 91.26 (-0.46), ATVI: 20.13 (-0.02), SAIC: 49.50 (-0.03), EVEP: 21.01 (+1.74), ONVO: 7.29 (+0.04), TRN: 28.28 (+0.27), CVX: 112.58 (+0.40), EEP: 40.55 (+0.65)

Jim Cramer's 'Mad Money' Recap: Goldilocks vs. 3 Bears, Where Nothing Is Just Right
at The Street - Tue Dec 16, 7:10PM CST
The bears may have won the day but there's still hope, Cramer says.
BLUE: 91.26 (-0.46), 77.49 (+0.59), RH: 95.14 (-0.87), COLM: 44.33 (-0.21), EEP: 40.55 (+0.65), TTWO: 28.09 (+0.06), ATVI: 20.13 (-0.02), PBR: 6.76 (-0.54), SAIC: 49.50 (-0.03), EVEP: 21.01 (+1.74), ONVO: 7.29 (+0.04), TRN: 28.28 (+0.27), CVX: 112.58 (+0.40)

Twitter's Favorite Biotech and Pharma Stocks
Brian Orelli, The Motley Fool - Motley Fool - Tue Dec 16, 8:21AM CST
Mark Schoenebaum, the biotech and pharmaceutical analyst at Evercore ISI, asked the Twittersphere for their favorite drug stocks going into next year. What's your favorite stock for 2015 in biotech or Pharma? — Mark Schoenebaum...
BLUE: 91.26 (-0.46), BMRN: 92.17 (+1.77), TGTX: 16.33 (+0.49), BMY: 59.51 (+0.48), MACK: 11.43 (+0.13), FMI: 22.18 (-0.04), RNA: 18.83 (+0.08), GWPH: 70.04 (+2.36), SRPT: 14.94 (+0.47), MRK: 57.19 (+0.40), NLNK: 43.65 (+3.90), ICPT: 159.49 (+3.49), THLD: 3.43 (+0.25), CEMP: 22.89 (-0.62), NVS: 92.25 (-0.41)

bluebird (BLUE) is in Overbought Territory: What's Next?

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Systemair Shakes Things Up: Closing Netherlands Facility

Systemair's Shocking Shutdown Decision Feels like we're strapped into a roller coaster with these HVAC companies lately. Systemair (NASDAQ Stockholm: SYSR) sure gave us quite the surprise ride by announcing they're pulling the plug on their production facility in Waalwijk, the Netherlands. This isn't just a ripple in a pond; it's a splash that might make some waves in the...

Z Squared Eyes 150 MW Expansion at Arkansas Site

Turning Power into Potential at Union County Next stop, Union County, Arkansas. Z Squared Inc. (Nasdaq: ZSQR) isn't just talking shop; they're getting down to work. With a freshly acquired site through Paradox Data, LLC, Z Squared's planning to turn vision into reality. The site's already armed with 8 MW of juice, all ready to roll, but their ambitions shoot up to 150 MW...

OneMain Holdings' Q3 2026: Mixed Signals in Nonprime Sector

Third Quarter Earnings: A Double-Edged Sword OneMain Holdings, Inc. (NYSE: OMF) rolled its Q3 2026 numbers out, and they look like a classic cocktail of high hopes and looming risks. On the surface, a diluted EPS of $1.60 might not sound like a knockout punch to the jaw, but let’s not forget they’ve taken a step back from last year’s $1.67. Their net income of $185...

Cork's Market Power Surges in U.S. Wine Industry

Cork: The Unsung Hero of the Wine Bottle You'd think a simple piece of bark couldn't shift the billion-dollar wine industry, but cork closures are doing just that. According to new NielsenIQ data, these natural stoppers are holding their ground as top dogs in the U.S. wine market. Who would've guessed that cork would drive the highest off-premise revenue? That's some...

Human Judgment Crucial Amid AI Growth in Courts

AI in the Justice System: Balancing Potential and Pitfalls You know, when it comes to upholding justice, there's a line between what machines can handle and what only a human can bring to the gavel. Chief Justice Sundaresh Menon of Singapore threw the spotlight on this at an event in Brisbane, hammering home the need for good ole human intuition in the courtroom even as...

Benewake Unveils SR Series LiDAR for Mobile Robots

Wave Goodbye to Bulky Sensors Hot off the Beijing press, Benewake's got something new—the SR Series 360° 3D LiDARs, set to stir up the robotics world. They're compact, power-efficient, and packed with smarts. It seems Benewake is tapping into a juicy market with these little sensors. Sleek Design and Big Promises The SR18 and SR96 models have a lot going for them. The...

Furniture Quality: Expert Tips for Savvy Shoppers

Picking Apart Furniture Quality Before a Purchase In a world where cheap and flashy often overshadow durability, knowing what makes furniture stand the test of time isn't just wise—it's essential. Learn from Nate Bartlett, the furniture sage from Charlevoix, Michigan, who guides shoppers through the maze of quality indicators in a recent HelloNation article. If you're...

Webull Faces Class Action: Investor Impact Deep Dive

What's Going On with Webull? Ah, Webull Corporation, you're in the hot seat now. If you blinked on October 7th, you might have missed a monumental 19.09% cliff dive in Webull's stock, tumbling down to a humble $5.89. The roar wasn't just the market reacting; it was the sonic boom of a class action lawsuit on their heels, alleging some slick legal sledding with misleading...

OCI Cleared to Merge with Orascom, Sets Delisting Date

OCI N.V. has hit a milestone. The shareholders have given the green light to merge with Orascom Construction PLC. This move is fleshed out with an updated roadmap that sharp-eyed investors need to watch closely. The company's shares will no longer be trading on Euronext Amsterdam by late November 2026, contingent on regulatory nods and other variables swirling in the...

Phrontline's TJ101 Gains Momentum in Cancer Clinical Trials

Encouraging Signs from Phrontline's TJ101 ADC Trials In the high-stakes race to outsmart cancer, Phrontline Biopharma is banking on TJ101, their star investigational bispecific antibody-drug conjugate (ADC). The recent results shared at the ESMO Congress 2026 are stirring up quite a bit of chatter. Urothelial Carcinoma and Beyond Now, picture this: six of eight evaluable...